Sign In
ALXN.US

Alexion (ALXN) $125M Shareholder Settlement

Claim deadline for this case already passed by, but we can still try and file for compensation for you
D. Connecticut
Court
3:16-cv-2127
Case number
30 Jan 2014
Class period Start
26 May 2017
Class period End
15 Dec 2023
Claim deadline
Alexion (ALXN) agreed to settle a $125 million with shareholders to end claims that the $ALXN caused a double-digit plunge in stock price after its allegedly illegal sales strategy came to light.
Alleged Offence
Misleading Statements
Failure to Disclose
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
0.76
Filing date
17 November 2016
Plaintiffs
Boston Retirement System, David A. Slossberg, Jeffrey P. Nichols
Attorneys
Labaton Sucharow LLP, Motley Rice LLC, Sturman LLC, Risch Pisca LLC
Defendants
Leonard Bell, David L. Hallal, Vikas Sinha
Judge
Hon. Alvin W. Thompson
Administrator
KCC
Settlement agreement date
2023-09-13
Court hearing date
20 December 2023
Exclusion deadline
29 November 2023
Objection deadline
29 November 2023
Hearing deadline
29 November 2023
Trades matching type
FIFO
+$125,000,000
Total Settlement Amount
Created by Stan Vick, Scout

Alexion Pharmaceuticals Inc

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemo...

    Ticker
    ALXN.US
    ISIN
    US0153511094
    CIK
    899866
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    121 Seaport Boulevard, Boston, MA, United States, 02210